TNDM Quote, Financials, Valuation and Earnings

iRhythm Holdings, Inc. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 2.67%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat iRhythm Holdings, Inc.'s return on equity of -40.07%.

Tandem Diabetes Care, Inc. has a consensus price target of $27.27, signalling upside risk potential of 10.08%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $212.87 which suggests that it could grow by 41.01%. Given that iRhythm Holdings, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.683, which suggesting that the stock is 68.285% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.245%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $208.9M. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than iRhythm Holdings, Inc.'s net income of $5.6M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.63x versus 6.52x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 27.89%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Tandem Diabetes Care, Inc. has a consensus price target of $27.27, signalling upside risk potential of 10.08%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 21.38%. Given that Intuitive Surgical, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.683, which suggesting that the stock is 68.285% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.63x versus 18.17x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 12.96%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Insulet Corp.'s return on equity of 17.89%.

Tandem Diabetes Care, Inc. has a consensus price target of $27.27, signalling upside risk potential of 10.08%. On the other hand Insulet Corp. has an analysts' consensus of $357.00 which suggests that it could grow by 47.59%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.683, which suggesting that the stock is 68.285% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.175%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Insulet Corp. quarterly revenues of $783.8M. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Insulet Corp.'s net income of $101.6M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 69.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.63x versus 6.39x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 11.84%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Stryker Corp.'s return on equity of 15.17%.

Tandem Diabetes Care, Inc. has a consensus price target of $27.27, signalling upside risk potential of 10.08%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 11.62%. Given that Stryker Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Stryker Corp. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.683, which suggesting that the stock is 68.285% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.89% to investors and pays a quarterly dividend of $0.88 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Stryker Corp.'s net income of $849M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Stryker Corp.'s PE ratio is 45.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.63x versus 5.85x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.